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INTRODUCTION
Atrial fibrillation (AF), the most common cardiac dysrhythmia, 
causes substantial morbidity.1-4 AF affects millions of patients 
and increases one’s risk of heart failure,5,6 stroke,7,8 and death.2,5 
The prevalence of AF increases with advancing age, and the 
older adult population is increasing worldwide.9-14 The preva-
lence of AF in Korea was 1.53% in 2015 and was reported as like-
ly to increase to 5.81% by 2060.15 Given these findings, an in-
creasing economic burden of AF on the health care system is 
anticipated, and it is important to estimate the cost and effec-
tiveness of different therapeutic options.10,16 
Several studies recently compared the economic practicality 
of non-vitamin K antagonist oral anticoagulants to adjusted-
dose warfarin for the prevention of stroke in AF.17-20 It is known 
that rate-control and rhythm-control drugs do not show signif-
icant differences in mortality rates.21,22 In a previous study in 
Korea, a rhythm-study strategy also showed no benefit on car-
diovascular mortality, compared with a rate-control strategy.23 
Meanwhile, economic studies comparing AF rate control ver-
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sus rhythm control have revealed that rate control reduces costs, 
compared with rhythm control, which included electrical car-
dioversion in Western individuals: The study involved 4060 
patient across 213 sites in Canada and the United States, with 
mean survival, resource use (hospital days, pacemaker proce-
dures, cardioversions, percutaneous transluminal coronary an-
gioplasties, coronary artery bypass graft procedures, valve surgery 
procedures, ablation, and short-stay and emergency department 
visits), costs, and cost-effectiveness compared as outcome in-
dicators between rate-control and rhythm-control groups. 
Rate-control drugs included digoxin, atenolol, metoprolol, pro-
pranolol, diltiazem, and verapamil, and rhythm-control drugs 
included flecainide, propafenone, quinidine, disopyramide, 
moricizine, amiodarone, sotalol, and dofetilide. Rate-control 
costs were $5077 less per person than those for rhythm con-
trol.24 However, the cost-effectiveness of treating AF with rate-
control and rhythm-control strategies has not been examined 
in Korea. The costs of drugs and hospitalization in Korea are 
different from those in Western countries. Moreover, recently, 
hospitalization for AF has increased by 420% from 767 to 3986 
per 1 million Korean populations from 2006 to 2015 and hos-
pitalization for AF control has increased compared with hos-
pitalization for ischemic stroke and myocardial infarction 
(MI).16 Based on these results, cost-effectiveness analysis may 
play a substantial role in treatment selection. Therefore, we 
sought to compare the projected quality-adjusted survival and 
costs of different rate-control and rhythm-control drugs in Ko-
rean patients with AF.  
MATERIALS AND METHODS
This study examined data from the National Health Insurance 
Service (NHIS) database. The NHIS is a single insurer con-
trolled by the Korean government, and the majority (97.1%) of 
Korean residents are mandatory subscribers, with the remain-
ing 3% being medical aid subjects. The sociodemographic in-
formation of patients, their use of inpatient and outpatient ser-
vices, pharmacy dispensing claims, and mortality data were 
extracted. This study was approved by the Institutional Review 
Board of Yonsei University Health System (4-2019-0802), which 
waived the need for informed consent.
Study population
In the Korean NHIS database, a total of 268149 patients with 
prevalent AF who were aged 18 years or older were identified 
between January 1, 2013 and December 31, 2015. Those with 
valvular AF, such as moderate to severe mitral valve stenosis 
and prosthetic valve disease [International Classification of 
Disease 10th Revision (ICD)-I050, I052, I342] were excluded. 
Finally, this study included 212459 and 55690 patients who 
were taking rate-control and rhythm-control drugs, respec-
tively. The rate-control drugs included digoxin, beta-adreno-
ceptor antagonists (atenolol, betaxolol, bevantolol, bisoprolol, 
carvedilol, propranolol), diltiazem, and verapamil, while the 
rhythm-control drugs included flecainide, propafenone, pilsi-
cainide, amiodarone, sotalol, and dronedarone (Table 1). 
AF was diagnosed using ICD-10 codes I48 (AF and atrial flut-
ter), I48.0 (AF), and I48.1 (atrial flutter). Moreover, patients were 
defined as having AF only when it was a discharge diagnosis or 
confirmed more than twice in the outpatient department to en-
sure diagnostic accuracy. The AF diagnosis was previously val-
idated in the NHIS database with a positive predictive value of 
94.1%. A validation study was performed in 628 randomly se-
lected patients with the ICD-10 code I48 at two separate institu-
tions. The patients’ electrocardiograms (ECGs) were reviewed 
by two physicians. Patients were defined as AF if documented 
by ECG.16,25,26 
Decision model
We developed a Markov chain Monte Carlo model to evaluate 
the cost-effectiveness of the rate- and rhythm-control drugs. 
Health states modeled included healthy AF, congestive heart 
failure (CHF), MI, ischemic stroke, transient ischemic attack 
(TIA), intracranial hemorrhage (ICH), gastrointestinal bleed-
ing (GI), and death. Cases of “fatal” CHF, MI, ischemic stroke, 
TIA, ICH, and GI bleeding were defined as transition to death. 
Table 1. Drugs Used to Treat Atrial Fibrillation in the Rate- and Rhythm-
Control Groups among Patients Newly Diagnosed with Atrial Fibrillation 
between January 1, 2013 and December 31, 2015 in Korea
Total
Years
2013 2014 2015
Rate control
Overall 212459 (100) 68182 (100) 69225 (100) 75052 (100)
Digoxin 39360 (17.2) 13235 (19.4) 13195 (19.1) 12930 (17.2)
Atenolol 10852 (4.2) 4242 (6.2) 3449 (5.0) 3161 (4.2)
Betaxolol 928 (0.4) 364 (0.5) 277 (0.4) 287 (0.4)
Bevantolol 536 (0.2) 212 (0.3) 172 (0.2) 152 (0.2)
Bisoprolol 49493 (23.8) 15410 (22.6) 16253 (23.5) 17830 (23.8)
Carvedilol 38412 (18.1) 12404 (18.2) 12398 (17.9) 13610 (18.1)
Propranolol 32854 (16.5) 9998 (14.7) 10473 (15.1) 12383 (16.5)
Diltiazem 24096 (11.2) 7893 (11.6) 7802 (11.3) 8401 (11.2)
Verapamil 4803 (2.2) 1695 (2.5) 1463 (2.1) 1645 (2.2)
Rhythm control
Overall 55690 (100) 16617 (100) 18758 (100) 20315 (100)
Flecainide 13914 (25.0) 4082 (24.6) 4616 (24.6) 5216 (25.7)
Propafenone 14078 (25.2) 4196 (25.2) 4792 (25.6) 5090 (25.1)
Pilsicainide 2890 (5.2) 1058 (6.4) 998 (5.3) 834 (4.1)
Amiodarone 21976 (39.5) 6547 (39.4) 7367 (39.3) 8062 (39.7)
Sotalol 1065 (1.9) 324 (1.9) 327 (1.7) 414 (2.0)
Dronedarone 1767 (3.2) 410 (2.5) 658 (3.5) 699 (3.4)
Values are presented as n (%). Reference: The National Health Insurance Ser-
vice. Nebivolol (2729; 4.0% in 2013, 3743; 5.4% in 2014, and 4653; 6.2% in 
2015) was excluded in cost-effectiveness analysis due to incomplete health 
event records.
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Non-fatal GI bleeding was assumed to be a transition to healthy 
AF. The health event was defined as newly diagnosed using 
ICD-10 codes for each event of CHF (I50.0, I11.0), MI (I21, I22), 
ischemic stroke (I63, I64), TIA (G45), ICH (I60, I61, I62), and GI 
bleeding (K92.2) within 1 year, considering that the transition 
cycle in the Markov model was 1 year in patients who had been 
on medication for more than 6 months after being newly di-
agnosed AF. We assumed that the healthy state transitioned 
annually based on the probability of an independent health 
event occurring within 1 year. The transition probabilities 
were estimated by cumulative incidence based on the data of 
the patients who were enrolled in this study between January 
1, 2013 and December 31, 2015 (Table 2, Fig. 1; Supplementary 
Fig. 1, only online). Drug adherence rates were assumed to be 
Table 2. Base-Case Values Used in Sensitivity Analysis of Rate- and Rhythm-Control Drugs among Patients Newly Diagnosed with Atrial Fibrillation 
between January 1, 2013 and December 31, 2015 in Korea
Drugs
CHF MI Ischemic stroke TIA ICH GI bleeding
Event (n)
Rate 
(%/year)
Event (n)
Rate 
(%/year)
Event (n)
Rate 
(%/year)
Event (n)
Rate 
(%/year)
Event (n)
Rate 
(%/year)
Event (n)
Rate 
(%/year)
Rate control
Digoxin (n=39360) 11238 28.6 1140 2.9 3251 8.3 563 1.4 367 0.9 324 0.8
Atenolol (n=10852) 1287 11.9 200 1.8 873 8.0 177 1.6 115 1.1 48 0.4
Betaxolol (n=928) 109 11.8 16 1.7 58 6.3 16 1.7 5 0.5 6 0.7
Bevantolol (n=536) 87 16.2 21 3.9 28 5.2 8 1.5 4 0.8 5 0.9
Bisoprolol (n=49493) 13995 28.3 1805 3.7 4112 8.3 768 1.6 511 1.0 300 0.6
Carvedilol (n=38412) 9456 24.6 1902 5.0 3116 8.1 555 1.4 423 1.1 261 0.7
Propranolol (n=32854) 3160 9.6 542 1.7 1590 4.8 480 1.5 409 1.2 172 0.5
Diltiazem (n=24096) 4110 17.1 786 3.3 1855 7.7 354 1.5 233 1.0 190 0.8
Verapamil (n=4803) 679 14.1 83 1.7 340 7.1 48 1.0 46 1.0 41 0.9
Rhythm control
Flecainide (n=13914) 2657 19.1 186 1.3 822 5.9 217 1.6 91 0.7 65 0.5
Propafenone (n=14078) 2530 18.0 172 1.2 753 5.4 236 1.7 93 0.7 60 0.4
Pilsicainide (n=2890) 456 15.8 34 1.2 141 4.9 47 1.6 18 0.6 21 0.7
Amiodarone (n=21976) 4873 22.2 930 4.2 1566 7.1 280 1.3 237 1.1 142 0.7
Sotalol (n=1065) 148 13.9 31 2.9 76 7.1 17 1.6 4 0.4 5 0.5
Dronedarone (n=1767) 292 16.5 57 3.2 96 5.4 27 1.5 4 0.2 14 0.8
CHF, congestive heart failure; MI, myocardial infarction; TIA, transient ischemic attack; ICH, intracranial hemorrhage; GI, gastrointestinal.
Distribution: normal. Reference: The National Health Insurance Service.
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Fig. 1. Decision tree model. The treatment strategies are shown on the left in patients with newly diagnosed atrial fibrillation between January 1, 2013 
and December 31, 2015 in Korea. Markov node (M) indicates a Markov process with eight health statuses and a cycle length of 1 year until death oc-
curred or the 20-year time horizon was reached. Probabilities of health events depend on the treatment. Patients could die of ischemic stroke, intra-
cranial hemorrhage, myocardial infarction, gastrointestinal bleeding, or other comorbidities. AF, atrial fibrillation.
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similar in all groups, and efficacy was assumed to be relatively 
constant. To ensure patient follow-up for a lifetime, a cycle 
length of year and a time horizon of 20 years were used. Each 
year, the cohort accrued costs and quality-adjusted life years 
(QALY) depending on which health state they inhabited. The 
model was built in TreeAge Pro 2012 (TreeAge Software, Inc., 
Williamstown, MA, USA).
Quality of life estimates
To measure quality-adjusted survival, QALY values were cal-
culated by multiplying life years by utility scores derived from 
the medical literature.27,28 By definition, death (from any cause) 
had a QALY of 0. The utility scores of CHF, MI, ischemic stroke, 
TIA, fatal GI bleeding, and ICH were 0.7, 0.9, 0.4, 0.8, 0.9, and 
0.4, respectively. The discount rate was set at annual 3%, re-
flecting the annual inflation rate in Korea.29 
Cost-effectiveness analysis 
The net cost for each treatment drug by QALY was quantified 
over a period of 20 years using a societal perspective. The cost 
consisted of annual drug costs, maintenance costs, and single 
event costs. Annual drug costs were defined as the drug cost per 
day during 1 year based on the NHIS database (Supplementary 
Table 1, only online). The event-related cost was estimated as 
the average cost of hospitalization for the health event (Sup-
plementary Table 2, only online). We estimated effectiveness 
(QALY) and the mean cost per tablet and year for the rate-con-
trol and rhythm-control groups. QALY and net costs were ad-
justed in each cycle related to the patients’ health states. Ac-
cording to the amount of time a person spent in a health state, 
QALY and the costs accrued for each Markov state were weight-
ed. Costs are expressed in US dollars, and the cost-effective-
ness of individual drugs (rate control and rhythm control) was 
compared with atenolol through cost-effectiveness ratio (cost 
per QALY) and incremental cost-effectiveness ratio (ICER), 
which can be used for informed decision-making when re-
sources are limited. Willing-to-pay was estimated at $30000 
US/QALY, reflecting the GDP for Korea (US $29745 in 2017). 
Korean won (KRW) was converted to US dollars ($1 US=1000 
KRW) in this analysis.
RESULTS
Number of prescriptions for each drug
During the study period, bisoprolol was the most commonly 
prescribed drug for rate control (23.8%), followed by carvedilol 
and digoxin (18.11% and 17.22%, respectively). Betaxolol and 
bevantolol had the lowest prescription rates (0.4% and 0.2%, 
respectively). Amiodarone was the most commonly pre-
scribed rhythm control drug (39.7%), followed by flecainide 
and propafenone (25.7% and 25.1%, respectively). Sotalol had 
the lowest prescription rate (2.0%), followed by pilsicainide 
and dronedarone (4.1% and 3.4%, respectively).
Incidence of health events
In an integrated analysis involving all drugs, the number of 
ischemic strokes per year for bisoprolol was highest (8.3%), 
while that for pilsicainide was lowest (4.9%). The number of 
TIA, ICH, GI bleeding, MI, and CHF events per year was highest 
for betaxolol, propranolol, bevantolol, carvedilol, and digoxin 
(1.7%, 1.2%, 0.9%, 5.0%, and 28.6%, respectively), while that for 
verapamil, dronedarone, propafenone, pilsicainide, and pro-
pranolol was lowest (1.0%, 0.2%, 0.4%, 1.2%, and 9.6%, respec-
tively). 
Cost-effectiveness of rate control medications
Among the rate-control medications, the cost per QALY for pro-
pranolol was lowest ($487/QALY), while that for carvedilol was 
highest ($1363/QALY). 
Based on base-case assumptions, the average lifetime treat-
ments costs of rate-control drugs and QALY were $10443 and 
13, respectively. The cost per QALY for atenolol was $714/QALY. 
Carvedilol had the highest cost per QALY ($1363/QALY), while 
propranolol had the lowest cost per QALY ($487/QALY). How-
ever, at a willingness-to-pay threshold of $30000 USD/QALY, 
all rate control drugs for treating AF were cost-effective. The 
incremental cost (-$1499) was lowest and incremental effec-
tiveness (3 QALY) was highest with propranolol, which reflect-
ed a more valuable ICER (-$577/QALY) than that with atenolol 
(Table 3, Fig. 2, Supplementary Fig. 2, only online). 
Cost-effectiveness of rhythm control medications
Patients taking rhythm-control drugs lived an average of 14 
QALY, with average lifetime treatments costs of $10745. Among 
the rhythm-control medications, the cost per QALY for pilsic-
ainide was lowest ($638/QALY), while that for amiodarone was 
highest ($986/QALY). Flecainide, propafenone, and dronedar-
one had costs per QALY of $834, $830, and $824/QALY, re-
spectively. Sotalol and pilsicainide had incremental cost ($453 
and $996) and incremental effectiveness (2 and 3 QALY), dem-
onstrating ICER values of $324/QALY and $332/QALY, respec-
tively, compared with atenolol. Equivalent to rate-control drugs, 
the cost-effectiveness thresholds of the rhythm-control drugs in 
this analysis were lower than $30000 per QALY (Table 3, Fig. 3, 
Supplementary Figs. 3 and 4, only online). 
Sensitivity analysis
Sensitivity analyses were performed to test uncertainty and to 
confirm the robustness of the results. The varying parameters 
in the analysis included discount rates of 5%, as well as 20% 
increases above previous assumptions for annual drug prices, 
annual maintenance costs, and costs of health incidents. The 
sensitivity analysis did not differ from the basic analysis de-
spite changes in the discount rate and cost (Supplementary 
Tables 3 and 4, only online).
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DISCUSSION
Our Markov chain Monte Carlo model showed that in patients 
treated with rate-control drugs, propranolol may be a cost-ef-
fective alternative to other agents in Korean patients with AF. 
Among rate-control drugs, propranolol showed the highest 
QALY and the lowest net cost, compared with atenolol. In pa-
tients taking rhythm-control drugs, sotalol and pilsicainide had 
lower net costs and increased QALYs, compared with atenolol. 
The present analysis demonstrated that propranolol, sotalol, 
and pilsicainide may be preferred alternatives based on costs 
among rate-control and rhythm-control drugs of use in Korea. 
Previous studies have described a non-significant trend to-
ward reduced survival in patients with AF who attempt rhythm 
control, compared with rate control.21-23,30,31 Since economic 
factors may play a considerable role in selecting treatment op-
tions, several authors have investigated the cost-effectiveness 
of rhythm- versus rate-control strategies for treating AF.24,32-34 
Eckman, et al.32 showed that cardioversion followed by the 
use of warfarin and amiodarone was the most effective strategy 
among several antiarrhythmic and antithrombotic treatment 
options. Catherwood, et al.33 found that cardioversion with or 
without antiarrhythmic drugs was more effective and less costly 
than rate-control drugs. Hagens, et al.34 demonstrated that 
treatment costs were higher for rhythm-control than rate-con-
trol drugs due to the higher costs of electrical cardioversion, 
Table 3. Projected Costs, QALYs, and ICERs for the Rate- and Rhythm-Control Drugs among Patients Newly Diagnosed with Atrial Fibrillation between 
January 1, 2013 and December 31, 2015 in Korea
Cost (USD) QALY
Cost  
per QALY
Incremental cost 
(reference atenolol)
Incremental QALY 
(reference atenolol)
ICER ($/QALY)
Rate control
Atenolol 8707 12 714 0 0 0
Propranolol 7208 15 487 -1499 3 -577
Betaxolol 8618 14 611 -90 2 -4
Verapamil 9477 13 718 769 1 769
Diltiazem 9518 13 732 810 1 1013
Bevantolol 10023 14 732 1315 2 877
Carvedilol 13084 10 1363 4376 -2 -1683
Digoxin 13487 11 1237 4780 -1 -3677
Bisoprolol 13868 13 1101 5161 1 12903
Rhythm control
Sotalol 9161 14 674 453 2 324
Pilsicainide 9704 15 638 996 3 332
Flecainide 10931 13 834 2224 1 2471
Propafenone 11282 14 830 2574 2 1839
Dronedarone 11457 14 824 2750 2 1618
Amiodarone 11931 12 986 3224 0 -32238
QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; USD, US dollars ($).
Propranolol
Betaxolol 
Atenolol
Verapamil
Diltiazem
Bevantolol
Bisoprolol
Digoxin
Carvedilol
0                                500                             1000                            1500
Cost-effectiveness (not costs per QALY, $US/QALY)
Fig. 2. Cost-effectiveness (bars) of rate-control drugs in patients with 
newly diagnosed atrial fibrillation between January 1, 2013 and Decem-
ber 31, 2015 in Korea. All drugs remained cost-effective at a willingness-
to-pay threshold of $30000 per quality-adjusted life year (QALY).
Fig. 3. Cost-effectiveness (bars) of rhythm-control drugs in patients with 
newly diagnosed atrial fibrillation between January 1, 2013 and Decem-
ber 31, 2015 in Korea. All drugs remained cost-effective at a willingness-
to-pay threshold of $30000 per quality-adjusted life years (QALY).
Pilsicainide
Sotalol
Atenolol
Dronedarone
Propafenone
Flecainide
Amiodarone
0                                500                            1000                          1500
Cost-effectiveness (not costs per QALY, $US/QALY)
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hospital admission, and medication in patients with persistent 
AF. However, these studies were limited by the lack of random-
ized data on efficacy and resource use. Marshall, et al.24 per-
formed an economic analysis of the Atrial Fibrillation Follow-
up Investigation of Rhythm Management (AFFIRM)21 results 
and found non-significant differences in mean survival time, 
although treatment costs were always higher in the rhythm 
control group. In that study, the drug cost per day was greater 
for all of the rhythm-control drugs than the rate-control drugs. 
The authors compared resource use data, including medications, 
hospital visits, cardiac procedures, and short-stay and emergen-
cy department visits. 
Here, we estimated the effectiveness (QALY) and mean net 
cost per year for individual rate- and rhythm-control drugs. 
Although bisoprolol and amiodarone were the most frequently 
prescribed drugs during the study period, we found that pro-
pranolol was the more cost-effective rate-control drug and that 
sotalol and pilsicainide were the most cost-effective rhythm-
control drugs. These findings were based on a comprehensive 
calculation of net costs, incremental costs, QALY, and ICER.
Our study has several limitations. First, because details on the 
quantification and doses of the prescribed medications and 
treatment adherence were not available, we assumed that each 
medication was taken properly at standardized doses. There-
fore, our data did not accurately reflect real life efficacy and 
safety because participants may exhibit superior medication 
adherence. Any misclassification would probably affect under- 
or overestimation of the true difference in drugs costs. Second, 
we only analyzed health events of ischemic stroke, TIA, ICH, 
GI bleeding, MI, and CHF using Korean NHIS data for 3 years. 
These data do not fully reflect the analysis contents of the study 
in real world practice. According to limited data from the Ko-
rean NHIS, we did not further assess the association between 
treatment strategy and other resource events or procedures, 
such as cardioversion or pacemaker implantation. Third, pa-
tients who took two or more drugs were assigned to each drug. 
One patient could be included in a drug category more than 
twice. Because drug-based analysis was performed, it was not 
possible to estimate the overall medications costs for each pa-
tient. Fourth, with a mean age of 66 years, our patients were rel-
atively old for patients with AF. Thus, while our results can be 
applied to AF patients in general, they probably cannot be gen-
eralized to younger patients with AF. Fifth, we assumed that 
any non-fatal GI bleeding would result in a healthy state. This 
may not always be the case and would likely be based on in-
dividual patient factors. Sixth, rhythm control strategies of 
guidelines in AF recommend specific class drugs depending on 
whether a patient has structural heart disease. However, we 
did an integrated analysis of rhythm-control drugs, regardless 
of the presence of cardiac structural abnormality. Therefore, 
direct comparison of cost-effectiveness among rhythm control 
drugs was not available in our study. Finally, much more work 
is needed to perform a cost-effectiveness analysis that can im-
prove health outcomes and save system-wide costs.
In conclusion, propranolol and pilsicainide were found to 
be cost-effective in patients with AF in Korea, assuming that 
drug usage or compliance is the same. Notwithstanding, in ad-
dition to cost-effectiveness, drug selection ought to consider 
drug safety, patient preference, and side effects. 
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